# OnCo record espac-4 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/espac-4/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "espac-4", "ISRCTN96397434" ;
  schema:name "ESPAC-4"@en ;
  schema:alternateName "ESPAC4"@en ;
  schema:description "ESPAC-4 showed that adding the tablet capecitabine to gemcitabine after pancreatic cancer surgery lengthened median survival from 25.5 to 28 months, and the pair became the adjuvant standard for people who cannot tolerate the harsher FOLFIRINOX regimen."@en ;
  schema:url <https://onco.cc/trials/espac-4/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.isrctn.com/ISRCTN96397434> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-neoptolemos-lancet-2017/> .